Newron Pharmaceuticals SPA

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Newron Pharmaceuticals SPA sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 6 completed early-phase tilt top decile by trial count

Newron Pharmaceuticals SPA: 9 sponsored US clinical trials, 1 recruiting.

Newron Pharmaceuticals SPA sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Treatment-resistant Schizophrenia, with 1 trials.

Top-decile sponsor footprint

Newron Pharmaceuticals SPA ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

NCT07184619
COMPLETED Phase 2

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

NCT04461119
TERMINATED Phase 2

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

NCT02790034
COMPLETED Phase 2

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

NCT02624167
COMPLETED Phase 1

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

NCT01955564
TERMINATED Phase 2

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

NCT01264861
COMPLETED Phase 2

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

NCT01211587
COMPLETED Phase 3

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

NCT00627640
COMPLETED Phase 3

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 5
Phase 3 3

Therapeutic Areas

Treatment-resistant Schizophrenia 1
Idiopathic Parkinson´s Disease 1

What is open in the Newron Pharmaceuticals SPA pipeline

1 recruiting of 9 indexed (11% open); 6 completed (67%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Treatment-resistant Schizophrenia (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Newron Pharmaceuticals SPA: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Newron Pharmaceuticals SPA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Newron Pharmaceuticals SPA4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Newron Pharmaceuticals SPA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Newron Pharmaceuticals SPA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Newron Pharmaceuticals SPA page

9 registered trials is a research-attention snapshot, not an endorsement of Newron Pharmaceuticals SPA or any single study.

  • 1 of Newron Pharmaceuticals SPA's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Treatment-resistant Schizophrenia is the condition Newron Pharmaceuticals SPA studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Treatment-resistant Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Newron Pharmaceuticals SPA pipeline card: 9 registered trials from official public datasets.Report a data error.